febuxostat has been researched along with topiroxostat in 23 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (topiroxostat) | Trials (topiroxostat) | Recent Studies (post-2010) (topiroxostat) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 80 | 17 | 69 |
| Protein | Taxonomy | febuxostat (IC50) | topiroxostat (IC50) |
|---|---|---|---|
| Xanthine dehydrogenase/oxidase | Bos taurus (cattle) | 0.8919 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 13 (56.52) | 24.3611 |
| 2020's | 7 (30.43) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, JW; Jung, SH; Kim, GT; Kim, TH; Park, H; Park, WS; Song, JU | 1 |
| Anderluh, M; Jakopin, Ž; Kocić, G; Petronijević, Ž; Šmelcerović, A; Šmelcerović, Ž; Tomašič, T; Tomović, K | 1 |
| Chen, H; Li, J; Li, Z; Liu, X; Wu, F; Zhang, L; Zou, Y | 1 |
| Chen, Y; Deng, L; Li, Z; Liu, Y; Nie, L; Xie, R; Xu, X | 1 |
| Fu, P; Li, X; Liu, J; Ma, L | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Nishino, T; Okamoto, K | 1 |
| Okamoto, K | 1 |
| Ichida, K | 1 |
| Ohya, M; Shigematsu, T | 1 |
| Hibi, C; Hirata, K; Hisamichi, M; Hoshino, S; Kamijo-Ikemori, A; Kimura, K; Murase, T; Nakamura, T; Oikawa, T; Shibagaki, Y; Sugaya, T | 1 |
| Ashizawa, N; Iwanaga, T; Morimoto, N; Murase, T; Nakamura, T; Nampei, M; Sakamoto, R | 1 |
| Hoshi, H; Kazama, JJ; Terawaki, H | 1 |
| Abe, K; Kanno, S; Obata, K; Sekino, H; Sezai, A | 1 |
| Mitsuboshi, S; Nagai, K; Okajima, H; Yamada, H | 1 |
| Bolignano, D; Buemi, M; Cernaro, V; D'Arrigo, G; Gembillo, G; Pisano, A | 1 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S | 1 |
| Borghi, C; Cicero, AFG; Cincione, RI; Fogacci, F; Tocci, G | 1 |
| Abe, Y; Fukumoto, Y; Hisatome, I; Hongou, M; Hoshide, S; Kario, K; Kasai, T; Kiuchi, M; Kiyosue, A; Kuga, H; Kuramochi, J; Miyazaki, S; Nishizawa, M; Ohtani, H; Tomita, F; Yasu, T | 1 |
| Borghi, C; Cicero, AFG; Fogacci, F; Kuwabara, M | 1 |
| Cheng, H; Hou, X; Li, X; Nan, G; Ren, L; Tian, J; Xiao, Z; Yan, D; Yang, Y; Ye, F | 1 |
| Iguchi, T; Ishiguro, C; Kajiyama, K; Kimura, R; Nakazato, Y; Oniyama, Y; Sawada, S; Shida, H; Uyama, Y | 1 |
9 review(s) available for febuxostat and topiroxostat
| Article | Year |
|---|---|
Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Topics: Allopurinol; Computer Simulation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Humans; Molecular Structure; Structure-Activity Relationship; Xanthine Oxidase | 2017 |
Pharmacological urate-lowering approaches in chronic kidney disease.
Topics: Biological Products; Drug Discovery; Flavonoids; Humans; Renal Insufficiency, Chronic; Uric Acid | 2019 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
[Inhibitors of xanthine oxidoreductase].
Topics: Allopurinol; Drug Design; Enzyme Inhibitors; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyrazoles; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
[New antihyperuricemic medicine: febuxostat, Puricase, etc].
Topics: Animals; Clinical Trials as Topic; Drug Design; Febuxostat; Gout Suppressants; Humans; Nitriles; Organic Anion Transporters; Organic Cation Transport Proteins; Polyethylene Glycols; Pyridines; Thiazoles; Urate Oxidase; Xanthine Dehydrogenase | 2008 |
Xanthine Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis.
Topics: Aged; Allopurinol; Enzyme Inhibitors; Febuxostat; Female; Humans; Male; Middle Aged; Nitriles; Pyridines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Xanthine Oxidase | 2017 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients.
Topics: Allopurinol; Benzaldehydes; Chronic Disease; Comorbidity; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Nitriles; Pyridines; Randomized Controlled Trials as Topic; Xanthine Oxidase | 2021 |
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Naphthalenes; Nitriles; Phenylacetates; Polyethylene Glycols; Probenecid; Propionates; Pyridines; Thioglycolates; Triazoles; Urate Oxidase; Uricosuric Agents; Xanthine Oxidase | 2021 |
3 trial(s) available for febuxostat and topiroxostat
| Article | Year |
|---|---|
Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial).
Topics: Adult; Aged; Anti-Inflammatory Agents; Antioxidants; Cardiovascular Diseases; Cross-Over Studies; Febuxostat; Female; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2017 |
Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial).
Topics: Aged; Antioxidants; Biomarkers; Cross-Over Studies; Down-Regulation; Enzyme Inhibitors; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2020 |
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Topics: Febuxostat; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Nitriles; Pyridines; Treatment Outcome; Uric Acid | 2021 |
11 other study(ies) available for febuxostat and topiroxostat
| Article | Year |
|---|---|
Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.
Topics: Administration, Oral; Animals; Binding Sites; Cattle; Drug Design; Enzyme Inhibitors; Half-Life; Hyperuricemia; Microsomes, Liver; Molecular Docking Simulation; Protein Structure, Tertiary; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Thiazoles; Uric Acid; Xanthine Oxidase | 2016 |
Synthesis and bioevaluation of 1-phenyl-pyrazole-4-carboxylic acid derivatives as potent xanthine oxidoreductase inhibitors.
Topics: Animals; Carboxylic Acids; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hyperuricemia; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Oxonic Acid; Pyrazoles; Structure-Activity Relationship; Xanthine Dehydrogenase | 2017 |
Discovery of 2-phenylthiazole-4-carboxylic acid, a novel and potent scaffold as xanthine oxidase inhibitors.
Topics: Drug Discovery; Enzyme Inhibitors; Febuxostat; Thiazolidines; Xanthine Oxidase | 2019 |
Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Topics: Allopurinol; Animals; Catalysis; Crystallization; Enzyme Inhibitors; Febuxostat; Molybdenum; Nitriles; Protein Conformation; Pyridines; Thiazoles; Xanthine Dehydrogenase | 2008 |
A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Topics: Enzyme Inhibitors; Febuxostat; Humans; Hyperuricemia; Nitriles; Pyridines; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Uric Acid; Xanthine Oxidase | 2014 |
Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury.
Topics: Adenine; Animals; Biomarkers; Fatty Acid-Binding Proteins; Febuxostat; Kidney; Kidney Diseases; Male; Mice; Mice, Transgenic; Nitriles; Pyridines; Xanthine Dehydrogenase | 2016 |
Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Topics: Albuminuria; Animals; Diabetic Nephropathies; Enzyme Inhibitors; Febuxostat; Male; Mice; Nitriles; Pyridines; Xanthine Dehydrogenase | 2016 |
Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Topics: Aged; Aged, 80 and over; Drug Substitution; Enzyme Inhibitors; Febuxostat; Female; Gout Suppressants; Humans; Hyperuricemia; Kidney; Male; Middle Aged; Nitriles; Proteinuria; Pyridines; Renal Insufficiency, Chronic; Treatment Outcome; Xanthine Dehydrogenase; Xanthine Oxidase | 2017 |
Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients.
Topics: Adult; Aged; Febuxostat; Female; Follow-Up Studies; Humans; Hyperuricemia; Male; Middle Aged; Nitriles; Prospective Studies; Pyridines; Renal Dialysis; Uric Acid; Uricosuric Agents | 2017 |
Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects.
Topics: Animals; Enzyme Inhibitors; Febuxostat; Gout; Hyperuricemia; Mice; Triazoles; Xanthine Dehydrogenase; Xanthine Oxidase | 2022 |
Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.
Topics: Allopurinol; Benzbromarone; Cardiovascular Diseases; Febuxostat; Gout; Gout Suppressants; Heart Disease Risk Factors; Humans; Insurance, Health; Japan; Risk Factors; Treatment Outcome; Uric Acid | 2023 |